Augusta University’s Sickle Cell Transition Program was recently awarded $50,000 from Global Blood Therapeutics, Inc., through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) grant program.
Augusta University’s Sickle Cell Transition Program was recently awarded $50,000 from Global Blood Therapeutics, Inc., through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) grant program.